Immunomedics, Inc. (NASDAQ:IMMU) Short Interest Down 5.5% in November

Share on StockTwits

Immunomedics, Inc. (NASDAQ:IMMU) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 29,940,000 shares, a decrease of 5.5% from the October 31st total of 31,680,000 shares. Based on an average daily trading volume, of 2,220,000 shares, the days-to-cover ratio is presently 13.5 days. Currently, 16.5% of the company’s stock are sold short.

Shares of IMMU stock opened at $18.78 on Monday. Immunomedics has a 12-month low of $11.55 and a 12-month high of $21.23. The firm has a market capitalization of $3.67 billion, a price-to-earnings ratio of -18.23 and a beta of 2.13. The business has a 50 day simple moving average of $16.84 and a 200 day simple moving average of $14.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 6.51 and a quick ratio of 6.51.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.09). During the same period last year, the company earned ($0.34) earnings per share. On average, equities analysts anticipate that Immunomedics will post -1.78 EPS for the current fiscal year.

In related news, insider Bryan Ball purchased 5,000 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were acquired at an average cost of $14.18 per share, for a total transaction of $70,900.00. Following the transaction, the insider now owns 10,000 shares of the company’s stock, valued at $141,800. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Avoro Capital Advisors Llc purchased 1,000,000 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $13.23 per share, for a total transaction of $13,230,000.00. The disclosure for this purchase can be found here. Corporate insiders own 9.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of IMMU. Arden Trust Co bought a new position in Immunomedics in the 2nd quarter worth approximately $143,000. Steward Partners Investment Advisory LLC bought a new position in Immunomedics during the 2nd quarter valued at $49,000. Creative Planning boosted its stake in Immunomedics by 3.7% during the 2nd quarter. Creative Planning now owns 242,528 shares of the biopharmaceutical company’s stock valued at $3,364,000 after purchasing an additional 8,672 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Immunomedics by 61.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 50,420 shares of the biopharmaceutical company’s stock valued at $699,000 after purchasing an additional 19,140 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Immunomedics by 3.2% during the 2nd quarter. Janus Henderson Group PLC now owns 3,956,289 shares of the biopharmaceutical company’s stock valued at $54,874,000 after purchasing an additional 124,387 shares in the last quarter. 83.57% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on IMMU shares. Piper Jaffray Companies increased their price target on Immunomedics from $20.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Jefferies Financial Group set a $22.00 price target on Immunomedics and gave the stock a “buy” rating in a research report on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Immunomedics in a research report on Thursday, October 31st. BidaskClub upgraded Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Cowen set a $30.00 price target on Immunomedics and gave the stock a “buy” rating in a research report on Sunday, September 29th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and an average target price of $26.22.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Read More: How is the Producer Price Index calculated?

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.